Health Trials

Clinical trials

2

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma

This is an open-label, multicenter Phase 1b/2a study to evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of GNS561 in combination with trametinib in Advanced KRAS Mutated Cholangiocarcinoma after failure of standard-of-care first line therapy

Participants needed: 98
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: GenfitUpdated: Jul 13, 2026Locations: 11
Eligibility criteria

Histologically confirmed intrahepatic CCA with a documented KRAS mutation. [+9]

Previous treatment with a MEK inhibitor or autophagy inhibitor. [+14]

Read more
Status: Not yet recruiting

Phase 2 Study of 500 mg BID NTZ on Top of Standard of Care in Patients With Acute Decompensation of Liver Cirrhosis at High Risk of Progression to Acute-on-Chronic Liver Failure or Established Acute-on-Chronic Liver Failure

Phase 2 Study of 500 mg BID NTZ on Top of Standard of Care in Patients with Acute Decompensation of Liver Cirrhosis at High Risk of Progression to Acute-on-Chronic Liver Failure or Established Acute-on-Chronic Liver Failure

Participants needed: 16
Trial details
Phase: Phase 2Age: 18-74Biological sex: AllType: InterventionalSponsor: GenfitUpdated: Jul 9, 2026
Eligibility criteria

Participants with liver cirrhosis of any underlying etiology (liver cirrhosis di... [+4]

Known hypersensitivity to nitazoxanide or any known excipient of the IMP [+11]

Read more